Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/001842COMBINATION FOR USE FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, CARDIOVASCULAR DISEASE AND METABOLIC SYNDROME
WO 26.01.2023
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/EP2022/070248 Applicant MEDA PHARMA S.P.A. Inventor ZANARDI, Andrea
The invention relates to a combination of: - naringin and - stanols for use in the treatment or prevention of hypercholesterolemia. The invention also relates to compositions comprising the combination.
2.WO/2023/003972CANCER TREATMENT COMBINATIONS
WO 26.01.2023
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No PCT/US2022/037755 Applicant VIRACTA SUBSIDIARY, INC. Inventor ROJKJAER, Lisa
Described herein is a method of treating a cancer or tumor in an individual, the method comprising administering to the individual afflicted with the cancer or tumor an effective amount of: a) nanatinostat; b) a nucleoside analog; c) and a checkpoint inhibitor antagonist.
3.WO/2023/000282CIRCIKBKB INHIBITOR AND USE OF CIRCLKBKB DETECTION REAGENT IN DIAGNOSIS, TREATMENT AND PROGNOSIS KIT FOR BREAST CANCER BONE METASTASIS
WO 26.01.2023
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Appl.No PCT/CN2021/108014 Applicant SUN YAT-SEN UNIVERSITY CANCER CENTER Inventor LI, Jun
The present invention belongs to the technical fields of biotechnology and medicine, and specifically relates to a circIKBKB inhibitor and the use of a circIKBKB detection reagent in a diagnosis, treatment and prognosis kit for breast cancer bone metastasis. The kit comprises one of RT-PCR, Q-PCR, Northern blot, FISH or ISH kits, and comprises primers as shown in SEQ ID NOs: 1-2 of the sequence list for a linker sequence of circIKBKB or a probe as shown in SEQ ID NO: 3 of the sequence list. The present invention also relates to an antisense oligonucleotide targeting a linker sequence of circIKBKB. The antisense oligonucleotide is used as a reagent for inhibiting the generation of circIKBKB and is used for preparing a drug for treating breast cancer bone metastasis; and the eIF4A3-IN-2 inhibitor is used for preparing a drug for treating breast cancer bone metastasis.
4.WO/2023/004437METHOD OF ENHANCING GENE THERAPY BY TARGETING CGAS-STING PATHWAY
WO 26.01.2023
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
Appl.No PCT/US2022/074084 Applicant SPARK THERAPEUTICS, INC. Inventor ANGUELA, Xavier
The present invention features method and composition that can be used to facilitate intracellular delivery of DNA to a subject. The provided methods and compositions employ a nanoparticle for intracellular DNA delivery and a cytosolic DNA-sensing inhibitor. The cytosolic DNA-sensing inhibitor is provided to decrease the subject's immune response that can be stimulated by the DNA.
5.WO/2023/000689PERIPHERAL BLOOD TCR MARKER FOR IGA NEPHROPATHY, DETECTION KIT THEREOF, AND APPLICATION THEREOF
WO 26.01.2023
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
Appl.No PCT/CN2022/080395 Applicant CHENGDU EXAB BIOTECHNOLOGY CO., LTD Inventor ZHANG, Zhixin
Disclosed are a peripheral blood TCR marker for IgA nephropathy, a detection kit thereof, and an application thereof. The marker comprises at least one of the proteins the sequences of which are shown in SEQ ID NO. 1-100. The present invention is based on a high-throughput sequencing method; only a small amount of peripheral blood needs to be taken to extract RNA, an immune big data library is established by processing samples, then high-throughput sequencing and TCR data analysis are performed; first a characteristic TCR sequence in peripheral blood of an individual suffering from IgA nephropathy is determined, and then a test result of a sample to be tested is aligned with the characteristic TCR sequence to thereby determine whether a patient has IgA nephropathy. In the present invention, a huge number of IgA nephropathy-specific TCR sequences can be compared simultaneously. Compared with detecting one or several markers alone, the present invention has higher specificity and accuracy, and improves diagnostic efficiency.
6.WO/2023/001724COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT
WO 26.01.2023
Int.Class A61K 31/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
Appl.No PCT/EP2022/069972 Applicant KETOSWISS AG Inventor GROSS, Elena
The present invention is in the field of pharmaceuticals, functional food products or supplements, and medical foods or food for special medical purposes (FSMP). In particular, the present invention relates to a combination of (i) a ketone body and/or a ketogenic compound, and (ii) an analgesic and/or an antioxidant, for use in treating and/or preventing pain such as headache, migraine and/or symptoms of migraine in a subject. Furthermore, the invention relates to a composition comprising (i) a ketone body and/or a ketogenic compound, and (ii) an analgesic and/or an antioxidant, such as a pharmaceutical composition, a food product, a food supplement, a nutritional aid, a medical food or food for special medical purposes (FSMP), and uses thereof.
7.WO/2023/002399DOSING REGIMEN FOR AN NLRP3 INHIBITOR IN THE TREATMENT OF OSTEOARTHRITIS
WO 26.01.2023
Int.Class A61K 31/426
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
4261,3-Thiazoles
Appl.No PCT/IB2022/056695 Applicant NOVARTIS AG Inventor COLEMAN, Laura
The present disclosure relates to the field of pharmacy, particularly to an NLRP3 inhibitor for use in the treatment of osteoarthritis. The disclosure also relates to an NLRP3 inhibitor or a pharmaceutical combination comprising an NLRP3 inhibitor, and at least one further therapeutic agent, for use in the treatment of osteoarthritis; to a method for the treatment of osteoarthritis that involves administering an NLRP3 inhibitor or the combination; and to the use of an NLRP3 inhibitor or the combination for the manufacture of a medicament for the treatment of osteoarthritis.
8.WO/2023/002219TREATMENTS OF HEREDITARY ANGIOEDEMA
WO 26.01.2023
Int.Class A61K 31/444
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Appl.No PCT/GB2022/051934 Applicant KALVISTA PHARMACEUTICALS LIMITED Inventor IVERSON, Matthew Scott
The present invention relates to treatments of hereditary angioedema (HAE) with a plasma kallikrein inhibitor and oral modified release pharmaceutical dosage forms comprising a plasma kallikrein inhibitor for use in these treatments.
9.WO/2023/004440STING AGONIST COMBINATION TREATMENTS WITH CYTOKINES
WO 26.01.2023
Int.Class A61K 31/7084
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
Appl.No PCT/US2022/074120 Applicant IMMUNESENSOR THERAPEUTICS, INC. Inventor CHEN, Zhijian
The disclosure provides, among other things, methods and uses for treating a disease or disorder, particularly tumors of a cancer patient, comprising conjointly administering effective amounts of a STING agonist, a cytokine, and an optional immune checkpoint inhibitor to the patient, wherein the STING agonist or the cytokine is intratumorally administered to the patient.
10.WO/2023/001264ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION
WO 26.01.2023
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/CN2022/107252 Applicant SHANGHAI BAO PHARMACEUTICALS CO., LTD. Inventor LIU, Yanjun
An antibiotic pharmaceutical composition for intradermal or subcutaneous administration, comprising antibiotics and hyaluronidase. Also provided are a kit comprising the pharmaceutical composition, a method for preparing the kit, and the use of the pharmaceutical composition and the kit.